A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

BioDrugs ◽

10.1007/s40259-021-00502-w ◽

2021 ◽

Author(s):

Steven R. Feldman ◽

Nataliya Reznichenko ◽

Grazyna Pulka ◽

Külli Kingo ◽

George Galdava ◽

...

Keyword(s):

Active Control ◽

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Control Phase ◽

Parallel Group ◽

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)79136-6 ◽

2009 ◽

Vol 2009 ◽

pp. 131-132

Author(s):

B.H. Thiers

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British Journal of Dermatology ◽

10.1111/bjd.18029 ◽

2019 ◽

Vol 181 (6) ◽

pp. 1177-1189 ◽

Cited By ~ 5

Author(s):

D. Thaçi ◽

K. Papp ◽

D. Marcoux ◽

L. Weibel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Term Efficacy ◽

Paediatric Patients ◽

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

The Lancet ◽

10.1016/s0140-6736(08)60593-0 ◽

2008 ◽

Vol 371 (9621) ◽

pp. 1337-1342 ◽

Cited By ~ 57

Author(s):

K Papp ◽

R Bissonnette ◽

L Rosoph ◽

N Wasel ◽

CW Lynde ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Faculty Opinions recommendation of Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962498.793465528 ◽

2012 ◽

Author(s):

David Alpers

Keyword(s):

Peritoneal Carcinomatosis ◽

Bowel Obstruction ◽

Symptomatic Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

PIII-38Long-term effects of ramelteon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled phase III study

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.246 ◽

2006 ◽

Vol 79 (2) ◽

pp. P68-P68 ◽

Cited By ~ 5

Author(s):

G RICHARDSON ◽

S WANGWEIGAND ◽

S SAINATI ◽

S DEMISSIE

Keyword(s):

Endocrine Function ◽

Phase Iii ◽

Chronic Insomnia ◽

Double Blind ◽

Double Blind Placebo ◽